Back to top
more

Valneva (VALN)

(Delayed Data from NSDQ)

$7.50 USD

7.50
21,442

+0.28 (3.90%)

Updated Aug 4, 2025 03:59 PM ET

After-Market: $7.45 -0.05 (-0.67%) 5:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Dynavax (DVAX) Up as EMA Accepts Valneva's COVID-19 Vaccine MAA

by Zacks Equity Research

Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.

Zacks Equity Research

Valneva (VALN) Down as EU Considers Ending COVID-Vaccine Deal

by Zacks Equity Research

Per the agreement with the European Commission, Valneva (VALN) has 30 days from May 13, 2022 to win a marketing authorization in the EU for its COVID vaccine or offer an acceptable remediation plan.

Zacks Equity Research

Valneva (VALN) Completes Phase III Chikungunya Vaccine Study

by Zacks Equity Research

Valneva's (VALN) phase III study evaluating its chikungunya vaccine achieves all primary and secondary endpoints. The stock rises 9.2% following the announcement.

Zacks Equity Research

Will Dynavax's (DVAX) Growth Momentum Continue in 2022?

by Zacks Equity Research

Year-over-year revenue growth for HEPLISAV-B and CpG 1018 adjuvant is expected to drive Dynavax???s (DVAX) profitability in 2022.

Zacks Equity Research

Valneva (VALN) Up as COVID-19 Jab Neutralizes Omicron Variant

by Zacks Equity Research

Three doses of Valneva's (VALN) inactivated COVID-19 vaccine candidate, VLA2001, neutralizes the Omicron variant of SARS-CoV-2, per data from preliminary lab studies. Shares rally.

Zacks Equity Research

Biotech Stock Roundup: REGN Gets EC Nod for Cocktail, BIIB's Drug Approval & More

by Zacks Equity Research

Drug approvals for Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.

Zacks Equity Research

Valneva (VALN) Stock Rises on Deal With EU for COVID-19 Jab

by Zacks Equity Research

Valneva (VALN) enters into a supply agreement for its COVID vaccine candidate with the European Commission. The stock price surges following the news.

Zacks Equity Research

Dynavax (DVAX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Dynavax's (DVAX) topline comprising sales of hepatitis B vaccine Heplisav-B, vaccine adjuvant CpG 1018 and other revenues is expected to retain the growth momentum in Q3 results.

Zacks Equity Research

Biotech Stock Roundup: BIIB's Q3 Earnings, REGN's COVID-19 Cocktail Update & More

by Zacks Equity Research

Regulatory and pipeline updates from bigwigs like Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.

Zacks Equity Research

Valneva (VALN) Reports Positive Data From COVID Vaccine Study

by Zacks Equity Research

Valneva's (VALN) shares surge after its COVID vaccine demonstrates superiority over AstraZeneca's COVID vaccine in a phase III study.

Zacks Equity Research

Pfizer (PFE) Submits COVID-19 Vaccine Data on Children to FDA

by Zacks Equity Research

Pfizer (PFE) and BioNTech plan to seek emergency use authorization for Comirnaty in children 5 to less than 12 years of age.

Zacks Equity Research

Valneva (VALN) Begins Submission for COVID-19 Vaccine in UK

by Zacks Equity Research

Valneva (VALN) starts rolling submission for the initial approval of its COVID-19 vaccine candidate, VLA2001, in the United Kingdom.